Alnylam Pharma (ALNY) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period
November 9, 2015 7:00 AM ESTAdvanced Late-Stage Clinical Pipeline: Patisiran APOLLO Phase 3 Trial on Track to Complete Enrollment in Next 3-4 Months; if Positive, Expect NDA Filing in 2017
Presented Positive Clinical Data for ALN-PCSsc for Hypercholesterolemia and ALN-AS1 for Acute Hepatic Porphyrias
Maintained Strong Balance Sheet with $1.34 Billion in Cash and Expect to End 2015 with Greater than $1.2 Billion in Cash
Hosting R&D Day on December 10, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
